Tags : TIDES

Takeda Reports Long-Term Safety and Efficacy Results of its Dengue

Tuba Khan May 24, 2021

Shots: The P-III TIDES study involves assessing two doses of TAK-003 (0.5mL, SC on day 1 & 90) vs PBO to prevent laboratory-confirmed symptomatic dengue fever of any severity and […]readmore

Pharma

Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial

Vartika Singh January 30, 2019

Shots: The P-III TIDES study contains three parts assessing TAK-003 (0.5ml, SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of […]readmore

Tags : TIDES

Takeda Reports Long-Term Safety and Efficacy Results of its Dengue

Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : TIDES

Takeda Reports Long-Term Safety and Efficacy Results of its Dengue

Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company